Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

BioVex

Biotech & Life Sciences · Woburn, United States · Founded 1999 Unicorn

Oncolytic virus therapies for cancer treatment

Valuation
$1–2.5B
Latest valuation · 2026
Unlock exact value
Headcount
<100
Current team size
Unlock exact value
Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026

Investors

19 investors on BioVex's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 19 investors entered at this stage
MVM Life Science Partners
Ysios Capital
Omnes Capital
Morningside
CLSA
Scottish Equity Partners
LDC
Temasek
ABN AMRO
Sectoral Asset Management
Ventech
Crédit Agricole
University College London
Forbion Capital Partners
Innoven Partners
New Science Ventures
Silicon Valley Bank
Triathlon Medical Venture Partners
Avalon Ventures

Global footprint

Where BioVex has talent and traffic

Workforce by country
2 countries with
team presence
🇺🇸 United States66.7%
🇬🇧 United Kingdom33.3%
2 countries shown

Market sentiment

What the market is saying about BioVex

An AI-synthesized read of the highest-engagement posts about BioVex on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See BioVex on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles